' 
![]()
SCIENTIFIC SCORE
Questionable
Based on 16 Researches
6.4
USERS' SCORE
Good
Based on 1 Reviews
8.5
Supplement Facts
Serving Size: 2 Tablets
Amount Per Serving
%DV
Magnesium (from 2,000 mg magnesiumlysinate glycinate chelate) (Albion®)
200 mg
48%
Top Medical Research Studies
7
Magnesium supplementation reduces atrial fibrillation
Clinician preference instrumental variable analysis of the effectiveness of magnesium supplementation for atrial fibrillation prophylaxis in critical care.
Directly addresses magnesium efficacy
We wanted to understand the effectiveness of magnesium supplementation in preventing atrial fibrillation, a common heart rhythm issue in critical care patients. In our study, we looked at patient data from a single center, analyzing the varied practices of bedside nurses regarding magnesium treatment.
By examining the approach of individual nurses, we identified two groups: those who tended to be liberal with magnesium administration and those who were more restrictive. Through rigorous analysis, we found that magnesium supplementation was linked to a 3% decrease in the relative risk of developing atrial fibrillation. This suggests that implementing routine magnesium treatment could be beneficial for patients.
While our findings support the idea of using magnesium to help prevent atrial fibrillation, we recognize that more research is needed to determine the best serum magnesium levels for maximum benefit. Overall, our study offers promising insights into how magnesium can play a role in improving patient care in critical settings.
By examining the approach of individual nurses, we identified two groups: those who tended to be liberal with magnesium administration and those who were more restrictive. Through rigorous analysis, we found that magnesium supplementation was linked to a 3% decrease in the relative risk of developing atrial fibrillation. This suggests that implementing routine magnesium treatment could be beneficial for patients.
While our findings support the idea of using magnesium to help prevent atrial fibrillation, we recognize that more research is needed to determine the best serum magnesium levels for maximum benefit. Overall, our study offers promising insights into how magnesium can play a role in improving patient care in critical settings.
Read More
9
Magnesium may reduce postoperative AF
Perioperative systemic magnesium sulfate minimizes the incidence of atrial fibrillation after thoracotomy for lung resection: a prospective observational study.
Significant findings in AF reduction.
We explored the impact of magnesium sulfate (MgS) on the occurrence of postoperative atrial fibrillation (POAF) in patients undergoing lung surgery via thoracotomy. In a prospective observational study involving 100 patients, we looked at how adding MgS to standard anesthetic management affected the rates of AF after surgery. MgS was given during anesthesia induction and through an infusion over 24 hours to assess its potential benefits.
While we found no significant impact on the first three days after surgery, by day seven, patients who received MgS showed a marked reduction in POAF compared to those who did not receive it. Specifically, the rates were 4% for the MgS group compared to 26% for the control group. Notably, in patients who were not on long-term beta-blockers, the benefits were even clearer, with only 14% experiencing AF compared to 80% in the control group.
Overall, our findings suggest that using magnesium sulfate may be a valuable strategy for lowering the risk of POAF, particularly for patients not already taking beta-blockers. This treatment approach could lead to smoother recoveries, shorter hospital stays, and potentially lower healthcare costs.
While we found no significant impact on the first three days after surgery, by day seven, patients who received MgS showed a marked reduction in POAF compared to those who did not receive it. Specifically, the rates were 4% for the MgS group compared to 26% for the control group. Notably, in patients who were not on long-term beta-blockers, the benefits were even clearer, with only 14% experiencing AF compared to 80% in the control group.
Overall, our findings suggest that using magnesium sulfate may be a valuable strategy for lowering the risk of POAF, particularly for patients not already taking beta-blockers. This treatment approach could lead to smoother recoveries, shorter hospital stays, and potentially lower healthcare costs.
Read More
8
Magnesium may reduce heart attack risk
Circulating Magnesium and Risk of Major Adverse Cardiac Events among Patients with Atrial Fibrillation in the ARIC Cohort.
Significant impact on heart events
We explored the connection between serum magnesium levels and major cardiovascular events among patients with atrial fibrillation (AF). The study involved 413 participants with AF, all of whom had their magnesium levels measured during a specific visit in the ARIC Study. Over an average follow-up of about 5.8 years, we monitored key health events such as heart failure, heart attacks, strokes, and overall mortality.
Our findings highlighted that higher serum magnesium levels were associated with a reduced risk of experiencing a heart attack. Specifically, participants in the highest magnesium group had an impressive 80% lower rate of heart attacks compared to those in the lowest group. While the improvements in other health outcomes were noted, they were not as striking, making it clear that the strongest benefit of magnesium focused primarily on heart attack risk.
Although we didn't find strong associations with every health endpoint studied, the evidence suggests that managing magnesium levels could play a beneficial role for those with atrial fibrillation. However, more research with larger cohorts is necessary to fully understand how magnesium might help in preventing adverse cardiovascular outcomes in these patients.
Our findings highlighted that higher serum magnesium levels were associated with a reduced risk of experiencing a heart attack. Specifically, participants in the highest magnesium group had an impressive 80% lower rate of heart attacks compared to those in the lowest group. While the improvements in other health outcomes were noted, they were not as striking, making it clear that the strongest benefit of magnesium focused primarily on heart attack risk.
Although we didn't find strong associations with every health endpoint studied, the evidence suggests that managing magnesium levels could play a beneficial role for those with atrial fibrillation. However, more research with larger cohorts is necessary to fully understand how magnesium might help in preventing adverse cardiovascular outcomes in these patients.
Read More
Most Useful Reviews
8.8
Positive results
After considerable online research on CHF and atrial fibrillation for my husband, we started taking Magnesium seven months ago. Both of us have experienced positive results; my husband saw fewer headaches and cramps. Last month, we also began taking CoQ10 along with d-ribose and l-carnitine. I feel exceptionally fit, which I attribute to these supplements.
Read More
Medical Researches
SCIENTIFIC SCORE
Questionable
Based on 16 Researches
6.4
9
Magnesium may reduce postoperative AF
Perioperative systemic magnesium sulfate minimizes the incidence of atrial fibrillation after thoracotomy for lung resection: a prospective observational study.
Significant findings in AF reduction.
We explored the impact of magnesium sulfate (MgS) on the occurrence of postoperative atrial fibrillation (POAF) in patients undergoing lung surgery via thoracotomy. In a prospective observational study involving 100 patients, we looked at how adding MgS to standard anesthetic management affected the rates of AF after surgery. MgS was given during anesthesia induction and through an infusion over 24 hours to assess its potential benefits.
While we found no significant impact on the first three days after surgery, by day seven, patients who received MgS showed a marked reduction in POAF compared to those who did not receive it. Specifically, the rates were 4% for the MgS group compared to 26% for the control group. Notably, in patients who were not on long-term beta-blockers, the benefits were even clearer, with only 14% experiencing AF compared to 80% in the control group.
Overall, our findings suggest that using magnesium sulfate may be a valuable strategy for lowering the risk of POAF, particularly for patients not already taking beta-blockers. This treatment approach could lead to smoother recoveries, shorter hospital stays, and potentially lower healthcare costs.
While we found no significant impact on the first three days after surgery, by day seven, patients who received MgS showed a marked reduction in POAF compared to those who did not receive it. Specifically, the rates were 4% for the MgS group compared to 26% for the control group. Notably, in patients who were not on long-term beta-blockers, the benefits were even clearer, with only 14% experiencing AF compared to 80% in the control group.
Overall, our findings suggest that using magnesium sulfate may be a valuable strategy for lowering the risk of POAF, particularly for patients not already taking beta-blockers. This treatment approach could lead to smoother recoveries, shorter hospital stays, and potentially lower healthcare costs.
Read More
8
Magnesium's uncertain impact on AF
External electrical and pharmacological cardioversion for atrial fibrillation, atrial flutter or atrial tachycardias: a network meta-analysis.
Score indicates limited significance
We investigated the role of magnesium among various treatments for atrial fibrillation (AF) in a comprehensive study reviewing multiple clinical trials. The analysis highlighted the effectiveness of both electrical and pharmacological cardioversion methods.
Magnesium was included in this analysis alongside other treatments like ibutilide and propafenone. However, the evidence for magnesium's specific impact on maintaining sinus rhythm was deemed low-certainty and not entirely definitive. We observed that while magnesium may show some promise, its effects were not as clearly established compared to the more robust outcomes seen with other medications.
Despite these findings, our study emphasizes the significance of patient profiles and treatment options available for managing AF. Although magnesium treatment is part of the conversation on atrial fibrillation management, its distinct benefits remain somewhat unclear when compared to other cardioversion methods.
Magnesium was included in this analysis alongside other treatments like ibutilide and propafenone. However, the evidence for magnesium's specific impact on maintaining sinus rhythm was deemed low-certainty and not entirely definitive. We observed that while magnesium may show some promise, its effects were not as clearly established compared to the more robust outcomes seen with other medications.
Despite these findings, our study emphasizes the significance of patient profiles and treatment options available for managing AF. Although magnesium treatment is part of the conversation on atrial fibrillation management, its distinct benefits remain somewhat unclear when compared to other cardioversion methods.
Read More
8
Magnesium's impact on AF
Impact of Dysmagnesemia on Atrial Fibrillation in Maintenance Hemodialysis Patients: A Nationwide Study.
Moderate relevance to AF treatment.
We conducted a nationwide study focusing on how serum magnesium (sMg) levels are linked to atrial fibrillation (AF) in patients undergoing hemodialysis. By analyzing data from 165,926 patients across 2,549 dialysis facilities in Japan, we aimed to assess if variations in magnesium levels truly influenced the occurrence of AF.
Our findings revealed that lower sMg levels could lead to a higher risk of AF. Specifically, patients with sMg levels less than 2.5 mg/dL showed increased odds of AF compared to those within the optimal range. Interestingly, those with sMg levels above this range had fewer cases of AF. This suggests that maintaining appropriate magnesium levels could be essential for heart rhythm stability.
However, we noted that while dysmagnesemia appears to contribute to AF in this population, there is still a need for further research. Longitudinal studies are necessary to truly determine if correcting magnesium levels can reduce AF incidence effectively. Ultimately, the connection between magnesium and atrial fibrillation is a complex one, and this study adds valuable insights to a growing body of evidence.
Our findings revealed that lower sMg levels could lead to a higher risk of AF. Specifically, patients with sMg levels less than 2.5 mg/dL showed increased odds of AF compared to those within the optimal range. Interestingly, those with sMg levels above this range had fewer cases of AF. This suggests that maintaining appropriate magnesium levels could be essential for heart rhythm stability.
However, we noted that while dysmagnesemia appears to contribute to AF in this population, there is still a need for further research. Longitudinal studies are necessary to truly determine if correcting magnesium levels can reduce AF incidence effectively. Ultimately, the connection between magnesium and atrial fibrillation is a complex one, and this study adds valuable insights to a growing body of evidence.
Read More
8
Magnesium aids AF cardioversion
Gender Differences With Ibutilide Effectiveness and Safety in Cardioversion of Atrial Fibrillation.
Study links magnesium with effectiveness
We explored the effects of magnesium treatment in patients with atrial fibrillation (AF) undergoing cardioversion with ibutilide. In our study, patients were carefully monitored; those with low magnesium levels received magnesium sulfate before ibutilide was administered.
The results showed that magnesium pretreatment improved patients' chances of converting back to a normal heart rhythm. Specifically, those who received magnesium saw a 70% success rate in returning to normal sinus rhythm (NSR).
We also noticed a significant gender difference in conversion rates—female patients converted to NSR at an impressive rate of 88%, compared to just 68% for males. This finding was interesting and may suggest that factors beyond magnesium alone contribute to treatment success in AF.
The results showed that magnesium pretreatment improved patients' chances of converting back to a normal heart rhythm. Specifically, those who received magnesium saw a 70% success rate in returning to normal sinus rhythm (NSR).
We also noticed a significant gender difference in conversion rates—female patients converted to NSR at an impressive rate of 88%, compared to just 68% for males. This finding was interesting and may suggest that factors beyond magnesium alone contribute to treatment success in AF.
Read More
8
Magnesium aids atrial fibrillation control
Efficacy of intravenous magnesium for the management of non-post operative atrial fibrillation with rapid ventricular response: A systematic review and meta-analysis.
Moderately relevant study findings
We evaluated the impact of intravenous magnesium (IV Mg) on patients experiencing atrial fibrillation (AF) with a rapid heartbeat. Our study involved a systematic review and meta-analysis of randomized controlled trials, comparing the effects of IV Mg to a placebo while patients received standard care.
Our analysis included nine trials with over a thousand patients. Remarkably, we found that IV Mg not only helped achieve better control over heart rate but also improved the chances of reverting to a normal rhythm. Specifically, it increased rate control by 87% and rhythm control by 45%, making it a promising addition to existing treatments.
We also noted that patients tolerated IV Mg well, and while side effects weren't reported in detail, there was no significant difference between groups regarding their occurrence. This suggests that magnesium could be a beneficial adjunct therapy for managing AF, especially for those who are not post-operative.
Our analysis included nine trials with over a thousand patients. Remarkably, we found that IV Mg not only helped achieve better control over heart rate but also improved the chances of reverting to a normal rhythm. Specifically, it increased rate control by 87% and rhythm control by 45%, making it a promising addition to existing treatments.
We also noted that patients tolerated IV Mg well, and while side effects weren't reported in detail, there was no significant difference between groups regarding their occurrence. This suggests that magnesium could be a beneficial adjunct therapy for managing AF, especially for those who are not post-operative.
Read More
User Reviews
USERS' SCORE
Good
Based on 1 Reviews
8.5
8.8
Positive results
After considerable online research on CHF and atrial fibrillation for my husband, we started taking Magnesium seven months ago. Both of us have experienced positive results; my husband saw fewer headaches and cramps. Last month, we also began taking CoQ10 along with d-ribose and l-carnitine. I feel exceptionally fit, which I attribute to these supplements.
Read More
